Though CD8+ T cells had a critical role in the anti-tumor effect, in the microenvironment of breast tumors succumbing to sulindac, we did not observed the increased frequency of tumor-infiltrating CD8+ T cells. The gene discussed is CD8A; the disease is breast neoplasm.